IDEX CORP /DE/ Q4 FY2024 earnings call

Management Statement and Operational Highlights

• IDEX teams navigated 2024's choppy macro conditions with operational focus, delivering innovative solutions and completing the Mott acquisition.
• Key themes in 2024 included initial growth signs, election cycle impact, and uncertain optimism in 2025.
• Strategic focus on capital deployment, thematic integration, pruning smaller businesses, and leveraging scale in five groups to target faster-growing markets.
• Mott's strong first quarter results, smooth integration, and FSDP setting new quarterly sales records were highlighted.

Segment Performance

• Health and Science Technology (HST): Fourth quarter organic growth 8%; full year organic decline 7% due to life sciences and semiconductor cyclical headwinds.
• Fire Safety and Diversified Product (FSDP): Fourth quarter organic growth 8%; full year low single-digit growth driven by North America Fire OEM and integrated system solutions.
• Fluid Management Technologies (FMT): Fourth quarter organic low single-digit decline; full year flat with strength in chemicals and municipal water offsetting softness in agriculture and semiconductor capital equipment.

Guidance

• Full-year 2025 organic revenue growth expected 1%-3%, with GAAP EPS $6.56-$6.96 and adjusted EPS $8.10-$8.45 (up 3%-7% vs 2024).
• First quarter 2025: GAAP EPS $1.18-$1.24, adjusted EPS $1.60-$1.65, organic revenue decline 3%-4%.
• Adjusted EBITDA margins expected 27.5%-28% for full year, 24.1%-24.5% for Q1.
• Platform optimization, deleveraging, price cost realization, and share-based comp impact EPS.

Risks

• Geopolitical tension and U.S. trade/economic policy uncertainty.
• Impact of inflation, interest rates, and policy changes on growth catalysts.
• Supply chain risks and potential tariff impacts.

Question and Answer Q: Mike Halloran asks about Q1 softness and end market improvement.

A: Abhi Khandelwal and Eric Ashleman discuss sequential Q4 to Q1 factors, project timing, share-based comp, and semi market green shoots.

Q: Vlad Bystricky inquires about tariff impacts and customer feedback.

A: Eric Ashleman addresses localized supply chain, mitigation efforts, and pricing protection.

Q: Nathan Jones asks about Q1 segment performance and financial impacts of platform optimization.

A: Abhi Khandelwal and Eric Ashleman discuss segment declines and SG&A/gross margin benefits from optimization.

Q: Deane Dray asks about growth investments and tone of business.

A: Eric Ashleman and Abhi Khandelwal talk about self-funded growth, stable industrial markets, and positive project discussions.

Q: Joe Giordano asks about semi market ramp and life science export restrictions.

A: Eric Ashleman addresses semi market inventory adjustments, long-term indicators, and life science lift.

Q: Brett Linzey asks about price cost phasing and HST comparables.

A: Abhi Khandelwal clarifies price cost spread phasing and HST life science comparables.

Q: Andrew Buscaglia asks about HST and FMT strategic acquisitions and cycles.

A: Eric Ashleman discusses HST long-term growth prospects and FMT market dynamics.

Q: Rob Wertheimer asks about HST reversion to mean growth.

A: Eric Ashleman talks about moderate HST growth projections and long-term prospects.